Pseudomonas Aeruginosa Infection Treatment Market Synopsis

Pseudomonas Aeruginosa Infection Treatment Market Size Was Valued at USD 1.39 Billion in 2023 and is Projected to Reach USD 2.37 Billion by 2032, Growing at a CAGR of 6.11% From 2024-2032.

Pseudomonas is a type of bacteria found commonly in the environment in soil and water. There are many types of Pseudomonas but the one that most often causes infections in human beings is Pseudomonas aeruginosa, Pseudomonas aeruginosa can cause infections in the blood, lungs (pneumonia), or even in the other parts of the body after surgery. It is a serious health issue worldwide with a mortality rate ranging from 18% to 61%, Pseudomonas Aeruginosa Infection is treated by a combination of medicines and antibiotics.

• Pseudomonas aeruginosa is commonly found in the environment and can spread to people in healthcare settings when they are exposed to water or soil that is contaminated with these bacteria. Resistant strains of the germ are also very likely to spread from one person to another through contaminated hands, equipment, or surfaces.
• Pseudomonas aeruginosa has a prevalence of 7.1%–7.3% among all healthcare-associated infections. The most common site of this infection is pneumonia, and it is the most common Gram-negative organism identified in nosocomial pneumonia. The prevalence of P. aeruginosa is been increasing at a very fast rate.
• Moreover, if seen in intensive care unit (ICU) patients, these bacteria are responsible for an even higher percentage of healthcare-associated infections. A large international observational point-prevalence study of infections in ICU patients found that Pseudomonas aeruginosa represented around 16.2% of patient infections and was the cause of 23% of all ICU-acquired infections, with a respiratory source being the most common site of this infection.
• Pseudomonas aeruginosa infection cases are been largely increasing over the past decade. The treatment of Pseudomonas aeruginosa infections is generally done with antibiotics, antibiotic therapy with several other medicines is an important treatment. The medication for these types of infections includes aminoglycosides (gentamicin, tobramycin, amikacin, netilmicin), carbapenems, cephalosporins, fluoroquinolones, penicillin with ?-lactamase inhibitors (BLI), monobactams (aztreonam), fosfomycin and polymyxins.

Pseudomonas Aeruginosa Infection Treatment Market Trend Analysis

Increasing Prevalence of Serious Infections Caused by Pseudomonas Aeruginosa and Most of Them Being Nosocomial Infections

• The rising number of P. aeruginosa cases across the world is the primary factor that is boosting the demand for P. aeruginosa infection treatment. Today, Pseudomonas aeruginosa is one of the most common pathogens that may prove fatal, these bacteria cause severe nosocomial infections and also it is well-known for their multidrug resistance and hypervirulence. Infections caused by P. aeruginosa are critical to curate routinely.
• According to the Global Burden of Diseases, Injuries, and Risk Factors Study, a study on 33 bacterial genera or species across 11 infectious syndromes conducted in 2019, from 13·7 million infection-related deaths in 2019, there were 7·7 million deaths associated with the 33 bacterial pathogens and 5 leading pathogens—Staphylococcus aureus, Escherichia coli, Streptococcus pneumoniae, Klebsiella pneumoniae, and Pseudomonas aeruginosa were responsible for 54·9% of deaths. The number shows how the bacteria has proved to be fatal. Such severity of infections is the main reason behind the greater demand for effective treatments for the same.
• Moreover, despite the decline in the mortality rate of P. aeruginosa infected from approximately 90% when it was first discovered in 1882 up to now which is around 54%-56%, complete control over the infections is still not possible. For instance, the Centers for Disease Control and Prevention (CDC), estimated 51,000 healthcare-associated P aeruginosa infections in US hospitals occurring each year. Hence due to emerging infections, the need for treatments is also growing.

Rapidly Developing Multi-Drug Resistance (Antibiotic Resistance) In the Bacteria Along with Continued Development of Advanced Therapeutic Strategies

• Among all the nosocomial pathogens, Pseudomonas aeruginosa is recognized to be the major cause of morbidity and mortality. Pseudomonas aeruginosa infections are rising rapidly and these infections have no effective treatment. In addition to this, drug resistance (the nature of bacteria to develop resistance) is also growing rapidly across the world which has made the treatment even more complicated.
• Pseudomonas aeruginosa infections can generally be treated with antibiotics. But, now the multi-drug resistance in Pseudomonas aeruginosa and the increase in the number of these bacteria in healthcare settings like hospitals or nursing homes are making the treatment more difficult. For example, In year 2017, multidrug-resistant P. aeruginosa caused an estimated 32,600 infections among hospitalized patients and 2,700 estimated deaths in the United States alone further it is found that P. aeruginosa infected about 51,000 patients in the US each year, with about 6700 being multidrug-resistant
• With this, the bacteria are constantly finding new ways to resist the effects of the antibiotics used to treat the infections they cause and such a multi-drug resistant nature of Pseudomonas aeruginosa has resulted in an urgent need for new research and innovation in the antibacterial field to develop the most effective treatment for such infections, and ultimately serving as an opportunity for the market of pseudomonas aeruginosa infection treatment.

Pseudomonas Aeruginosa Infection Treatment Market Segment Analysis:

Pseudomonas Aeruginosa Infection Treatment market segments cover the Treatment Type, Drug Type, Route of Administration, and Distribution Channel.

By Treatment Type, Combination Treatment segment is expected to dominate the market during the forecast period

• Combination antibiotic therapy holds the largest share in the P. aeruginosa Infection Treatment Market. The reason behind the success of the segment is the extensive use of combination antibiotic therapy for severe pseudomonal infections.  Combination treatment is standard practice across many hospitals and healthcare centers when it comes to the treatment of P. aeruginosa.
• Combination therapy proves to be very effective on multi-drug resistant bacteria, some of the benefits include in vitro antibiotic synergy, prevention of the emergence of bacterial resistance while receiving therapy, and improved adequacy of empiric therapy.
• Combination therapy also helps in increasing compliance and efficacy, faster onset of action and it also reduces side effects and overall cost. These factors are leading to a rise in demand for combination therapy for the treatment of Pseudomonas aeruginosa infection which is ultimately fuelling the growth of the Pseudomonas Aeruginosa Infection Treatment Market.

By Distribution Channel, the Hospital Pharmacy segment held the largest share of 45.8% in 2022

• Hospital pharmacies play a pivotal role as the largest distribution channel segment for the Pseudomonas Aeruginosa Infection Treatment Market. These pharmacies serve as crucial hubs within healthcare ecosystems, acting as a bridge between healthcare providers and patients.
• The prevalence of Pseudomonas Aeruginosa infections, known for their resistance to many antibiotics, necessitates specialized medications and treatments that are often available exclusively through hospital pharmacies. These establishments are equipped to handle the complexities of infectious disease management, ensuring timely access to advanced pharmaceutical interventions.
• In hospital pharmacies, healthcare professionals collaborate closely to tailor treatment plans based on the specific needs of patients battling Pseudomonas Aeruginosa infections. The dynamic nature of these settings enables rapid response to emerging challenges, allowing for the efficient distribution of cutting-edge medications and therapeutic solutions.
• Additionally, hospital pharmacies serve as educational hubs, providing crucial information to both healthcare practitioners and patients about the latest advancements in Pseudomonas Aeruginosa infection treatment. As central pillars of the healthcare infrastructure, hospital pharmacies contribute significantly to the accessibility, efficacy, and safety of treatments for this challenging infection, fostering a comprehensive and patient-centered approach to care.

Pseudomonas Aeruginosa Infection Treatment Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• Increasing healthcare-associated infections (HAI) and rising technological innovations in the medical field in North American countries are mainly expected to drive the growth of the market in the region. According to the Statistics, more than 2.8 million antimicrobial-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. Also, according to a multistate point prevalence survey conducted by the CDC in 2014 shows that about 4% of hospitalized patients suffered from at least one of the HAI in the United States. 
• Further speaking about Canada, according to a report published in January 2022, each year, many Canadians acquire an infection during their hospital stay that increases mortality and costs heavily to the healthcare system. It is estimated that around 220,000 Canadian patients develop healthcare-associated infections (HAIs). Hence, such rising infection across developed countries like the US and Canada is expected to propel the market growth over the forecast period.
• In addition to this, government initiatives and funding for combatting antimicrobial resistance are continued in these countries and such implementation of national initiatives aimed at financially incentivizing the research and development (R&D) of antibiotics is boosting the market growth in the region.

Pseudomonas Aeruginosa Infection Treatment Market Top Key Players:

• Pfizer Inc. (USA)
• Merck & Co., Inc. (USA)
• Johnson & Johnson (USA)
• Cubist Pharmaceuticals (USA)
• Melinta Therapeutics (USA)
• Mylan N.V.  (USA)
• GlaxoSmithKline plc (UK)
• AstraZeneca plc (UK)
• Novartis AG (Switzerland)
• Roche Holding AG (Switzerland)
• Basilea Pharmaceutica (Switzerland)
• Sandoz International GmbH (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• BioMérieux SA (France)
• Sanofi (France)
• Cipla Ltd. (India)
• Lupin Limited (India)
• Dr. Reddy's Laboratories (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Biocon Ltd. (India)
• Shionogi & Co., Ltd. (Japan)
• Meiji Seika Pharma Co., Ltd. (Japan) and Other Major Players

Key Industry Developments in the Pseudomonas Aeruginosa Infection Treatment Market:

• In October 2023, BiomX Inc. successfully concluded patient dosing in Phase 1b/2a Part 2 trial of BX004, a pioneering phage cocktail designed for treating chronic pulmonary infections in cystic fibrosis patients caused by Pseudomonas aeruginosa., BX004 addresses a critical unmet need for effective treatments against persistent lung infections. Jonathan Solomon, CEO of BiomX, expresses optimism following the positive reception of Part 1 results at esteemed conferences, emphasizing growing interest in the BX004 program within the cystic fibrosis community. The company's commitment to advancing phage therapies positions BX004 as a promising solution.
• In December 2022, Clarametyx Biosciences began a Phase I clinical trial of CMTX-101, an immune-enabling antibody therapy, to treat community-acquired bacterial pneumonia.
• In March 2022, The National Institute of Allergy and Infectious Diseases (NIAID) awarded a roughly USD 2.5 million grant to two University of Maryland School of Pharmacy (UMSOP) staff members to examine how infections caused by the bacteria Pseudomonas aeruginosa develop multidrug resistance.